Open AccessThe Impact of Anlotinib on Brain Metastases of Non‐Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)
Author(s) -
Jiang Shunjun,
Liang Hengrui,
Liu Zhichao,
Zhao Shen,
Liu Jun,
Xie Zhanhong,
Wang Wei,
Zhang Yalei,
Han Baohui,
He Jianxing,
Liang Wenhua
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2019-0838
Subject(s) - medicine , hazard ratio , oncology , lung cancer , post hoc analysis , placebo , confounding , confidence interval , progression free survival , gastroenterology , overall survival , pathology , alternative medicine
Background Anlotinib has been shown to prolong progression‐free survival (PFS) and overall survival (OS) for non‐small cell lung cancer (NSCLC). Herein we sought to analyze the effect of anlotinib in managing brain metastases (BM) and its brain‐associated toxicities. Methods The PFS and OS of anlotinib versus placebo in those with and without BM recorded at baseline were calculated and compared respectively. Time to brain progression (TTBP), a direct indicator of intracranial control, was also compared between anlotinib and placebo. All calculations were adjusted for confounding factors, including stage, histology, driver mutation type, and therapy history. Results A total of 437 patients were included; 97 cases were recorded with BM at baseline. For patients with BM at baseline, anlotinib was associated with longer PFS (hazard ratio [HR], 0.29; 95% confidence interval [CI], 0.15–0.56) and OS (HR, 0.72; 95% CI, 0.42–1.12), presenting similar extent of improvement in those without BM (PFS: HR, 0.33; 95% CI, 0.24–0.45; OS: HR, 0.67; 95% CI, 0.50–0.91). Specifically, the intracranial objective response rate was 14.3% and the disease control rate was 85.7% in patients with BM who were treated with anlotinib. Anlotinib was associated with longer TTBP (HR, 0.11; 95% CI, 0.03–0.41; p = .001) despite all confounders. Additionally, anlotinib was associated with more neural toxicities (18.4% vs. 8.4%) and psychological symptoms (49.3% vs. 35.7%) but not with infarction or cerebral hemorrhage. Conclusion Anlotinib can benefit patients with advanced NSCLC with BM and is highly potent in the management of intracranial lesions. Its special effect on BM and cerebral tissue merits further investigation. ( ClinicalTrials.gov ID: NCT02388919).